The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
WALTHAM, Mass., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company developing novel precision antibacterials to treat ...
Entasis Therapeutics steered its lead antibiotic candidate through late-stage clinical development with help from Innoviva, which has steadily invested in the company over the past two years and now ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
WALTHAM, Mass., May 03, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel ...
Randomized, open label trial will assess the efficacy and safety of zoliflodacin versus a combination of azithromycin and ceftriaxone, the current standard of care 87 million new gonorrhea infections ...
Entasis Therapeutics has filed to raise up to $86 million through an IPO. The AstraZeneca spinout is seeking the money to fund a phase 3 trial of a drug to overcome bacterial resistance to ...
WALTHAM, Mass., April 16, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel ...
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. Entasis Therapeutics, Inc. (NASDAQ: ETTX) has seen its ...
The U.S. dithers, Europe ponders and the extinction of life-saving antibiotics continues apace. Here we go again. Entasis Therapeutics has been struggling in the public marketplace. There is certainly ...
Entasis Scores! The FDA's anti-infectives advisory board unanimously recommended approval of Entasis sulbactam-durlobactam for the treatment of hospital and ventilator-acquired pneumonia, caused by ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. WASHINGTON — Entasis Therapeutics announced at the World ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results